Background Psoriasis is a common skin disease and moderate to severe psoriasis is
associated with a dose-dependent risk for metabolic and cardiovascular morbidity. It has …

Background There is a need to evaluate severity of psoriasis with a simple, patient-assessed
instrument. Objective To investigate whether the self-administered Psoriasis Area and …

The self-administered psoriasis area and severity index (SAPASI) is a structured instrument
for measuring the severity of psoriasis. This study examines the validity, reliability, and …

A prospective observational study was conducted to analyze to what extent the Psoriasis
Area and Severity Index (PASI) is correlated to patient reported outcomes (PRO). Data were …

Summary Background The Psoriasis Area and Severity Index (PASI) is the most frequently
used clinical severity scale in clinical trials. Drug approval often depends on a 75 …

Although the demand for evidence-based decisions is increasing in clinical practice, recent
systematic reviews on the accuracy of existing psoriasis severity scales, including the …

Background The Psoriasis Area and Severity Index (PASI) is considered the gold standard
assessment tool for psoriasis severity, but PASI is limited by its complexity and insensitivity …

Background: Understanding the epidemiology of moderate-to-severe psoriasis is essential
for its management. Objective: To assess the epidemiological characteristics of patients with …

Because of the difficulty and expense of objectively measuring psoriasis severity, very little
information exists on the severity of psoriasis in populations. We determined severity in a …

The Psoriasis Area and Severity Index (PASI) is used by dermatologic investigators to
assess psoriasis disease severity. PASI measures are time-consuming and require trained …